Menu
1 min read · estimated
APPROVED USE
What FDA approved
To reduce the incidence and severity of doxorubicin-related cardiomyopathy in women with metastatic breast cancer who reached a cumulative 300 mg/m² of doxorubicin and would continue it for tumor control.
LAMPGEN ANALYSIS
Why it matters
Added a cardioprotective use to the Totect label for a defined cumulative-exposure group.
What research teams should watch
Reconcile cumulative anthracycline exposure and coordinate treatment timing and cardiac monitoring.
PRIMARY RECORDS